MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study
November 03, 2009 02:30 PM US Eastern Timezone MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with... [read full story]
|
RELATED
|
|
Nanostart Majority-Owned MagForce Announces Successful Completion Of Final Clinical Trials For...
MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in...
Nanostart to Feature Successful Completion of MagForce Clinical Trials at Investor Presentation...
Marco Beckmann, CEO of Nanostart AG , the global nanotechnology investment company based in Frankfurt, will be presenting the company and its portfolio holdings to an audience of approx. 80 selected investors and analysts on...
MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients
MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma. The primary study endpoint,...
DGAP-News: Nanostart to feature successful completion of MagForce clinical trials at investor...
Nanostart AG / Miscellaneous 04.11.2009 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. - Exclusive event...
Nanostart Majority-Owned MagForce Announces Successful Completion of Final Clinical Trials For...
November 03, 2009 09:06 AM US Eastern Timezone Study objective significantly exceeded FRANKFURT & BERLIN-- --MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today...
MagForce Nanotechnologies Completes Clinical Trial on Efficacy of Thermotherapy using Nanoparticles
MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma. The primary study endpoint,...
MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study
More News related to Press Releases BERLIN--(BUSINESS WIRE)-- MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in...
Nanostart Majority-Owned MagForce Announces Successful Completion of Final Clinical Trials For...
Therapy shown to be highly effective, with minimal side effects Application for EU regulatory approval to be submitted before end of year MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned...
MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study
BERLIN--(BUSINESS WIRE)--Nov 3, 2009 - MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent...
MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study
MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma. The primary study endpoint,...
Related categories
International Editions
English - US | English - UK | Deutsch | Français | Español - España | Português - Portugal | Italiano | Čeština | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese) | Español - México | Português - Brasil | 한국어 (Korean) | English - India
